Phase I studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic colorectal cancerAnne Flament(Celyad (Belgium)), Frédéric Lehmann(Télécom Paris)Annals of OncologyOctober 1, 201810.1093/annonc/mdy281.157Cited by 1SaveCiteExport RISWatch citationsRelated PapersSelection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma|Journal of Clinical Oncology|2013|222